Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895515 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAOAMAOBKDM1A | |
| SCHEMBL3468969 | 1.00 | OPRM1 (0.42) | OPRM1OPRL1MAOAMAOBKDM1A | |
| SCHEMBL13823155 | 0.78 | PGR (0.32) | — | |
| SCHEMBL10235158 | 0.77 | TAAR1 (0.34) | — | |
| SCHEMBL13864262 | 0.76 | HTR2A (0.35) | SLC6A3SLC6A4SLC6A2HTR2CCHRNB2 | |
| SCHEMBL11479521 | 0.76 | HTR2A (0.39) | OPRM1OPRL1MAOAKDM1ASLC6A3 | |
| SCHEMBL17729483 | 0.72 | MAOA (0.50) | OPRM1OPRL1MAOAMAOBKDM1A | |
| SCHEMBL31312513 | 0.71 | OPRL1 (0.44) | OPRM1OPRL1MAOAMAOBKDM1A | |
| SCHEMBL19387668 | 0.69 | SLC6A2 (0.51) | SLC6A3SLC6A4SLC6A2KCNH2 | |
| SCHEMBL27100094 | 0.68 | OPRM1 (0.45) | OPRM1OPRL1MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8217168-B2 | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| EP-2205560-B1 | AZABICYCLO [3. 1. 0]HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-12-28 | — | — | EP | disclosed |
| EP-2205560-B1 | AZABICYCLO [3. 1. 0]HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-12-28 | — | — | EP | disclosed |
| US-7863299-B2 | Triazolyl derivatives of azabicyclo [3.1.0] hexane as dopamine D3 receptor modulators | GLAXO GROUP LIMITED (GB) | 2011-01-04 | — | — | US | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| WO-2009043884-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| US-20080242715-A1 | Triazolyl Derivatives of Azabicyclo [3.1.0] Hexane as Dopamine D3 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240661-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, CHRNA5, NR3C2 | OPRM1 113/4885OPRL1 40/4885MAOA 1469/4885 |
| US-20080242715-A1 | Triazolyl Derivatives of Azabicyclo [3.1.0] Hexane as Dopamine D3 Receptor Modulators | CHRM1, CHRM5, CHRM2 | OPRM1 38/4885OPRL1 56/4885MAOA 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.